Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer

Immunohistochemical assessment of PTEN in vulvar cancer: Best practices for tissue staining, evaluation, and clinical association

(2015) A.M. Lavorato-Rocha et al.   METHODS

Role of aberrant PI3K pathway activation in gallbladder tumorigenesis

(2015) Andrea Lunardi et al.   Oncotarget

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

(2014) Brian A. Costello et al.   INVESTIGATIONAL NEW DRUGS

Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition

(2014) Huajie Zong et al.   MOLECULAR BIOLOGY REPORTS

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

(2014) R. Dienstmann et al.   MOLECULAR CANCER THERAPEUTICS

Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway

(2014) Maolan Li et al.   NATURE GENETICS

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis

(2014) Alberto Ocana et al.   PLoS One

Achieving cancer cell death with PI3K/mTOR-targeted therapies

(2013) Sung Su Yea et al.   Annals of the New York Academy of Sciences

PTEN modulators: a patent review

(2013) Chandra S Boosani et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer

(2013) Brian Shuch et al.   JOURNAL OF UROLOGY

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Regional Differences in Gallbladder Cancer Pathogenesis: Insights from a Comparison of Cell Cycle-Regulatory, PI3K, and Pro-Angiogenic Protein Expression

(2012) Jean M. Butte et al.   ANNALS OF SURGICAL ONCOLOGY

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing

(2012) Bojana Djordjevic et al.   MODERN PATHOLOGY

PTEN Level in Tumor Suppression: How Much Is Too Little?

(2011) A. Carracedo et al.   CANCER RESEARCH

Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma

(2011) Dong-Cai Liu et al.   PATHOLOGY RESEARCH AND PRACTICE

High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

(2011) Lydia W.T. Cheung et al.   Cancer Discovery

Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study

(2010) Xinglai Ji et al.   BMC CANCER

Epidemiology of Gallbladder Cancer

(2010) Guy D. Eslick   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma

(2010) Rita A. Sakr et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Gallbladder cancer: a morphological and molecular update

(2009) Robert David Goldin et al.   HISTOPATHOLOGY

Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations

(2009) Qinglong Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

Geographic variation of gallbladder cancer mortality and risk factors in Chile: A population‐based ecologic study

(2008) Marcelo E. Andia et al.   INTERNATIONAL JOURNAL OF CANCER

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE